The Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for Ebola in DR Congo to Fight the Current Largest Ever and Expanding Ebola Outbreak to Begin Soon - BioSpace
• NanoViricides has received regulatory approval to launch a Phase II clinical trial for NV-387 oral gummies to treat Ebola in the Democratic Republic of Congo. • The trial aims to combat the current outbreak, which is described as the largest and most expanding in the region's history. • Led by Professor Katoto and supported by experts like Fogarty Fellow Patrick, the study leverages specialized implementation research networks to scale novel treatments.
biospace.com
